Recent Updates
Recently added Catalysts

KalVista Pharmaceuticals, Inc.

KALV
Pharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$27
▲ 0 · 0%

Last traded Jun 10, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full KALV financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $9.8352W HIGH $26.85
Volume
4.27 M
Value Traded
173.31 M
Short % Float
19.69%
+0.04%Week
+34.96%1 Month
+71.62%3 Month
+106.55%6 Month
+4%5 Year
-70.57%All Time

Cash Data

Unlock KALV cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.43 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.43 B
Total Shares
50.58 M
Float Shares
34.75 M
Insiders
17.04%
Institutions
115.54%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every KALV catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

KALV Catalyst Timeline

Dated clinical, regulatory and corporate events for KalVista Pharmaceuticals, Inc.

Unlock the full KALV catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How KALV actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30EKTERLY (sebetralstat) NDA Submission NDA
Unlock 2 more KALV historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D36 / 100
Pipeline Score
$38M
Pipeline Value
Not rated
Valuation Signal
2
Drugs Scored
-
rNPV / MCap
KalVista Pharmaceuticals, Inc. faces pipeline headwinds (36/100), with $94M risk-adjusted pipeline value, led by KVD824 Prototype 1 modified-release in Hereditary Angioedema (Phase 1).
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
KVD824 Prototype 1 modified-release Small moleculeCompletedNCT05118958Hereditary AngioedemaPhase 1 COMPLETED 37Dec 1, 2020
Unlock the KALV pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every KALV program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
sebetralstat hereditary angioedemaPhase 32026-03-02attacks treated: 2464; second dose use: 19.3%; conventional treatment use: 5.1%; patient satisfaction: 83.1%; total attacks reported: 2077; oral sebetralstat use: 82.1%; untreated attacks: 1.9%; conventional use decrease: 21% to 13%; sebetralstat use increase: 76% to 85%Read MoreKalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)Read More
Scroll for more · summaries link to the source press release
Unlock every KALV trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock KALV insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Yea ChristopherOfficer (CHIEF DEVELOPMENT OFFICER)Option 33,800 263,718 held$7.07 05/27/2026
Unlock the full KALV insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in KALV

Fund % of Portfolio Current MV Shares Owned Activity
VR Adviser, LLC 4.9 % (-9.3 %) 130.33 M 6.47 M -3.78% ( -254.50 K)
Unlock every fund holding KALV
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in KALV
Shares held by hedge funds each quarter, and who bought or sold.

KALV Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock KALV option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live KALV option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock KALV options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How KALV ranks across every disease it competes in

Competitive Position is a premium feature
See how KALV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

KALV News

About KalVista Pharmaceuticals, Inc.

Framingham, MA 270 employees kalvista.com
Headquarters200 CROSSING BOULEVARD, FRAMINGHAM, MA, 01702
BIOPHARMAWATCH ELITE PLUS
Trade the next KALV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime